Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
Marcus
N
N
Imperial College School of Medicine at Harefield Hospital, Middlesex, UK.
Khaghani
A
A
Burke
M
M
Yacoub
M
M
Banner
N
N
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D006334:Heart Function Tests; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D001379:Azathioprine; D016559:Tacrolimus